Genetic or pharmacologic ATX silencing prevented the development of bleomycin-induced pulmonary fibrosis [4, 11], leading to ongoing phase III clinical trials in IPF patients [12]. The gene discussed is ENPP2; the disease is pulmonary fibrosis.